$Microsoft(MSFT.US$
where is the big sharks
where is the big sharks
$Arm Holdings(ARM.US$
Arm-based circuits are part of some of the most advanced AI systems made by Nvidia, the leader in AI computing.
Arm-based circuits are part of some of the most advanced AI systems made by Nvidia, the leader in AI computing.
1
恩祖
voted
$NVIDIA(NVDA.US$ i seen it cross 500 will it cross 600
恩祖
voted
There is always news about China's largest e-commerce company these days.
After the news of splitting up the business and ecosystem of $Alibaba(BABA.US$ $BABA-SW(09988.HK$, the latest news on Alibaba is the change of guard.
Meet Joseph Tsai, who will be the next Chairman of Alibaba.
A few points to take note of about Joseph Tsai and why the change of guard.
1. Co-founder & vice Executive Chairman of Alibaba
Many would have thought Jack Ma was the sole found...
After the news of splitting up the business and ecosystem of $Alibaba(BABA.US$ $BABA-SW(09988.HK$, the latest news on Alibaba is the change of guard.
Meet Joseph Tsai, who will be the next Chairman of Alibaba.
A few points to take note of about Joseph Tsai and why the change of guard.
1. Co-founder & vice Executive Chairman of Alibaba
Many would have thought Jack Ma was the sole found...
10
1
恩祖
commented on
$Union Gas(1F2.SG$ Why drop ah 🤔🤔
Translated
2
$Paysafe(PSFE.US$
(MT Newswires) -- Paysafe (PSFE) said Monday it has agreed to provide cash services to customers of the app-based Dutch bank bunq.Under the collaboration, bunq customers can use Paysafecash to add cash into their bunq accounts.The service will initially be available in 21 European countries.
(MT Newswires) -- Paysafe (PSFE) said Monday it has agreed to provide cash services to customers of the app-based Dutch bank bunq.Under the collaboration, bunq customers can use Paysafecash to add cash into their bunq accounts.The service will initially be available in 21 European countries.
1
恩祖
commented on
3
恩祖
commented on
$UP Fintech(TIGR.US$ DEAD TIGER
3
1
恩祖
commented on
$Aprea Therapeutics(APRE.US$
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September
16 – 21, 2021.
Details for the ESMO 2021 mini oral presentation are as follows:
Title: Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Speaker: Haeseong Park, Washington University in St. Louis Presentation #: 516MO
Session: Mini oral session – Developmental therapeutics
Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT)
GlobeNewswire, Inc. 2021
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for eprenetapopt in combination with pembrolizumab for the treatment of advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2021 from September
16 – 21, 2021.
Details for the ESMO 2021 mini oral presentation are as follows:
Title: Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Speaker: Haeseong Park, Washington University in St. Louis Presentation #: 516MO
Session: Mini oral session – Developmental therapeutics
Date and Time: Monday, September 20, 2021; 17:35 – 17:40 CEST (11:35 – 11:40am EDT)
GlobeNewswire, Inc. 2021
1